ACTR-73. A PHASE II STUDY OF TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED, UNRESECTABLE GLIOBLASTOMA

Por Sumrall, Ashley, Haggstrom, Daniel, Burri, Stuart, Symanowski, James
Publicado no Neuro Oncol (2017)

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Por Hall, Richard D., Le, Tri M., Haggstrom, Daniel E., Gentzler, Ryan D.
Publicado no Transl Lung Cancer Res (2015)

QLIF-42. INCIDENCE AND CHARACTERIZATION OF DERMATOLOGIC ADVERSE EVENTS IN PATIENTS TREATED WITH TUMOR TREATING FIELDS AND IMPACT ON OVERALL SURVIVAL

Por Sumrall, Ashley, Perera, Serena, Haggstrom, Daniel, Jennings, David, Symanowski, James, Robinson, Myra
Publicado no Neuro Oncol (2017)

ATNT-27 ASSESSING THE SAFETY OF COMBINATION THERAPY WITH BEVACIZUMAB AND OPTUNETM FOR HIGH GRADE GLIOMAS

Por Sumrall, Ashley, Haggstrom, Daniel, Asher, Tony, Crimaldi, Anthony, Prabhu, Roshan, Wait, Scott, Burri, Stuart
Publicado no Neuro Oncol (2015)

ATNT-28 MANAGING RECURRENT GRADE III GLIOMAS WITH COMBINATION THERAPY OF BEVACIZUMAB AND OPTUNETM

Por Sumrall, Ashley, Haggstrom, Daniel, Asher, Tony, Crimaldi, Anthony, Prabhu, Roshan, Wait, Scott, Burri, Stuart
Publicado no Neuro Oncol (2015)